Aravive Biologics’ AVB-S6-500 receives FDA fast track designation for ovarian cancer
Aravive Biologics, a biopharmaceutical company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel drug AVB-S6-500, aimed at treating platinum-resistant recurrent ovarian cancer. This significant regulatory milestone accelerates the drug’s development and potential commercialization, addressing an urgent need for new treatments in this challenging cancer subtype. AVB-S6-500 is […]